Christophe Hotermans

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

Gary Bloomgren, Sandra Richman, Christophe Hotermans et al. · New England Journal of Medicine · 2012 · 1.2K citations · Full text

Life Sciences, Neurology, Pharmacotherapy +17

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing

Lana Zhovtis Ryerson, John Foley, Ih Chang et al. · Neurology · 2019 · 194 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

Helmut Butzkueven, Ludwig Kappos, Fabio Pellegrini et al. · Journal of Neurology Neurosurgery & Psychiatry · 2014 · 175 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +16

Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome

Darin T. Okuda, Orhun H. Kantarci, Christine Lebrun‐Frénay et al. · Annals of Neurology · 2022 · 134 citations

Medicine, Neurology, Pharmacotherapy +17

Early boost and slow consolidation in motor skill learning

Christophe Hotermans, Philippe Peigneux, Alain Maertens de Noordhout et al. · Learning & Memory · 2006 · 119 citations · Full text

Social Sciences, Neuroscience, Psychology +14